AU2016311426B2 - Compounds and compositions useful for treating disorders related to NTRK - Google Patents
Compounds and compositions useful for treating disorders related to NTRK Download PDFInfo
- Publication number
- AU2016311426B2 AU2016311426B2 AU2016311426A AU2016311426A AU2016311426B2 AU 2016311426 B2 AU2016311426 B2 AU 2016311426B2 AU 2016311426 A AU2016311426 A AU 2016311426A AU 2016311426 A AU2016311426 A AU 2016311426A AU 2016311426 B2 AU2016311426 B2 AU 2016311426B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- ring
- mmol
- pharmaceutically acceptable
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XBCHDVAMSIDEKV-ZIAGYGMSSA-N CN(Cc(cc(cc1)F)c1F)C(c1n[nH]c2ncnc(N[C@H](CCC3)[C@@H]3O)c12)=O Chemical compound CN(Cc(cc(cc1)F)c1F)C(c1n[nH]c2ncnc(N[C@H](CCC3)[C@@H]3O)c12)=O XBCHDVAMSIDEKV-ZIAGYGMSSA-N 0.000 description 1
- RLJWCUKRKNQEBR-MMGJPBGESA-N CN(Cc(cc(cc1)[Cl-])c1C#N)C(c1n[nH]c2ncnc(N[C@H]([C@@H](C3)[C@@H]3[C@H]3O)[C@@H]3O)c12)=O Chemical compound CN(Cc(cc(cc1)[Cl-])c1C#N)C(c1n[nH]c2ncnc(N[C@H]([C@@H](C3)[C@@H]3[C@H]3O)[C@@H]3O)c12)=O RLJWCUKRKNQEBR-MMGJPBGESA-N 0.000 description 1
- FZNVRTIUIDHFDC-HSMVNMDESA-N CN(Cc(cc(cc1F)F)c1F)C(c1n[nH]c2ncnc(N[C@H](COC[C@H]3O)[C@@H]3O)c12)=O Chemical compound CN(Cc(cc(cc1F)F)c1F)C(c1n[nH]c2ncnc(N[C@H](COC[C@H]3O)[C@@H]3O)c12)=O FZNVRTIUIDHFDC-HSMVNMDESA-N 0.000 description 1
- NKKYUXKHMSOZCF-JMSVASOKSA-N CN(Cc1cc(F)cnc1)C(c1n[nH]c2ncnc(N[C@H](CC[C@H]3O)[C@@H]3O)c12)=O Chemical compound CN(Cc1cc(F)cnc1)C(c1n[nH]c2ncnc(N[C@H](CC[C@H]3O)[C@@H]3O)c12)=O NKKYUXKHMSOZCF-JMSVASOKSA-N 0.000 description 1
- GLXBNPYWDOZDLB-IOASZLSFSA-N CN(Cc1ccccc1)C(c1n[nH]c2ncnc(N[C@H](CC[C@H]3O)[C@@H]3O)c12)=O Chemical compound CN(Cc1ccccc1)C(c1n[nH]c2ncnc(N[C@H](CC[C@H]3O)[C@@H]3O)c12)=O GLXBNPYWDOZDLB-IOASZLSFSA-N 0.000 description 1
- MJBJLXSFLYYYNB-RNPDWPAJSA-N C[C@H](C[C@H]1Nc2c(c(C(N(C[C@H](C3)F)[C@H]3c3cncc(F)c3)=O)n[nH]3)c3ncn2)C[C@H]1O Chemical compound C[C@H](C[C@H]1Nc2c(c(C(N(C[C@H](C3)F)[C@H]3c3cncc(F)c3)=O)n[nH]3)c3ncn2)C[C@H]1O MJBJLXSFLYYYNB-RNPDWPAJSA-N 0.000 description 1
- IDVFQQZSIKXUAJ-VUNQCBSOSA-N N#Cc1cc([C@@H](C[C@@H](C2)F)N2C(c2n[nH]c3ncnc(N[C@H]([C@@H](C4)[C@@H]4[C@H]4O)[C@@H]4O)c23)=O)cc(F)c1 Chemical compound N#Cc1cc([C@@H](C[C@@H](C2)F)N2C(c2n[nH]c3ncnc(N[C@H]([C@@H](C4)[C@@H]4[C@H]4O)[C@@H]4O)c23)=O)cc(F)c1 IDVFQQZSIKXUAJ-VUNQCBSOSA-N 0.000 description 1
- BDDIIFIIQADRJJ-JQWIXIFHSA-N O=C(c1n[nH]c2ncnc(N[C@@H](C[C@@H](C3)F)C3=O)c12)NCc(cc(cc1)F)c1F Chemical compound O=C(c1n[nH]c2ncnc(N[C@@H](C[C@@H](C3)F)C3=O)c12)NCc(cc(cc1)F)c1F BDDIIFIIQADRJJ-JQWIXIFHSA-N 0.000 description 1
- CMPKYIOCUOXKJG-LALPHHSUSA-N O[C@@H]([C@@H](CC1)Nc2c(c(C(NCc(cc(cc3)F)c3F)=O)n[nH]3)c3ncn2)[C@@H]1F Chemical compound O[C@@H]([C@@H](CC1)Nc2c(c(C(NCc(cc(cc3)F)c3F)=O)n[nH]3)c3ncn2)[C@@H]1F CMPKYIOCUOXKJG-LALPHHSUSA-N 0.000 description 1
- ZBSWMGDLSSMYTH-MEXWJNSZSA-N O[C@H](CCC[C@H]1Nc2c(c(C(N(C[C@H](C3)F)[C@H]3c3cc(F)cc(Cl)c3)=O)n[nH]3)c3ncn2)[C@H]1O Chemical compound O[C@H](CCC[C@H]1Nc2c(c(C(N(C[C@H](C3)F)[C@H]3c3cc(F)cc(Cl)c3)=O)n[nH]3)c3ncn2)[C@H]1O ZBSWMGDLSSMYTH-MEXWJNSZSA-N 0.000 description 1
- ZVSUKLDNSQRBAE-RAIGVLPGSA-N O[C@H](C[C@@H](C1)F)[C@@H]1Nc1c(c(C(NCc(cc(cc2)F)c2F)=O)n[nH]2)c2ncn1 Chemical compound O[C@H](C[C@@H](C1)F)[C@@H]1Nc1c(c(C(NCc(cc(cc2)F)c2F)=O)n[nH]2)c2ncn1 ZVSUKLDNSQRBAE-RAIGVLPGSA-N 0.000 description 1
- LSJUVVNDLCSHDE-KABGHNSYSA-N O[C@H]([C@H](C1)[C@H]1C1)[C@@H]1Nc1c(c(C(NCc(cc(cc2)F)c2F)=O)n[nH]2)c2ncn1 Chemical compound O[C@H]([C@H](C1)[C@H]1C1)[C@@H]1Nc1c(c(C(NCc(cc(cc2)F)c2F)=O)n[nH]2)c2ncn1 LSJUVVNDLCSHDE-KABGHNSYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210264P | 2015-08-26 | 2015-08-26 | |
| US62/210,264 | 2015-08-26 | ||
| PCT/US2016/048698 WO2017035354A1 (en) | 2015-08-26 | 2016-08-25 | Compounds and compositions useful for treating disorders related to ntrk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016311426A1 AU2016311426A1 (en) | 2018-04-05 |
| AU2016311426B2 true AU2016311426B2 (en) | 2021-05-20 |
Family
ID=56896780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016311426A Expired - Fee Related AU2016311426B2 (en) | 2015-08-26 | 2016-08-25 | Compounds and compositions useful for treating disorders related to NTRK |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10017512B2 (enExample) |
| EP (1) | EP3341374A1 (enExample) |
| JP (1) | JP6877407B2 (enExample) |
| KR (1) | KR20180043810A (enExample) |
| CN (1) | CN108137607B (enExample) |
| AR (1) | AR105836A1 (enExample) |
| AU (1) | AU2016311426B2 (enExample) |
| BR (1) | BR112018003588A2 (enExample) |
| CA (1) | CA2995997A1 (enExample) |
| HK (1) | HK1255330A1 (enExample) |
| IL (1) | IL257702A (enExample) |
| MX (1) | MX2018002407A (enExample) |
| PH (1) | PH12018500397A1 (enExample) |
| RU (1) | RU2744974C2 (enExample) |
| TW (1) | TW201713665A (enExample) |
| WO (1) | WO2017035354A1 (enExample) |
| ZA (1) | ZA201801881B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| BR112016008541B1 (pt) | 2013-10-17 | 2022-11-22 | Blueprint Medicines Corporation | Composto ou sal farmaceuticamente aceitável, uso do mesmo para tratar mastocistose, tumor do estroma gastrointestinal e leucemia, e composição farmacêutica |
| AU2014339972B9 (en) | 2013-10-25 | 2019-05-30 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| KR20180048635A (ko) | 2015-07-24 | 2018-05-10 | 블루프린트 메디신즈 코포레이션 | Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물 |
| RU2744974C2 (ru) | 2015-08-26 | 2021-03-17 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk |
| IL302209B2 (en) | 2015-11-02 | 2024-06-01 | Blueprint Medicines Corp | Inhibitors of ret |
| CA3005741A1 (en) | 2015-11-19 | 2017-05-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| EP4285996A3 (en) | 2016-04-15 | 2024-01-10 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| CN113735881A (zh) | 2017-08-23 | 2021-12-03 | 正大天晴药业集团股份有限公司 | 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途 |
| CN111566102B (zh) | 2017-10-18 | 2023-09-08 | 缆图药品公司 | 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶 |
| CN111936138B (zh) * | 2018-02-05 | 2024-03-08 | 深圳市原力生命科学有限公司 | 作为ep4受体拮抗剂的杂二环化合物 |
| CN111971287B (zh) * | 2018-03-28 | 2023-06-02 | 重庆复尚源创医药技术有限公司 | 作为trk激酶抑制剂的大环化合物 |
| PT3773589T (pt) | 2018-04-03 | 2024-02-06 | Blueprint Medicines Corp | Inibidor de ret para utilização no tratamento de cancro com alteração de ret |
| KR20220012221A (ko) * | 2019-02-27 | 2022-02-03 | 페로 테라퓨틱스 인코포레이티드 | 페롭토시스 유도 활성을 갖는 화합물 및 이의 사용 방법 |
| EP3856341B1 (en) | 2019-04-12 | 2023-09-06 | Blueprint Medicines Corporation | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
| JP7787812B2 (ja) * | 2019-11-25 | 2025-12-17 | アルカームス インコーポレーテッド | 置換大環状化合物および関連する治療方法 |
| CA3183728A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| CN113408945B (zh) * | 2021-07-15 | 2023-03-24 | 广西中烟工业有限责任公司 | 一种烤烟纯度的检测方法、装置、电子设备及存储介质 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998014450A1 (en) * | 1996-10-02 | 1998-04-09 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| PL224879B1 (pl) | 2002-09-04 | 2017-02-28 | Pharmacopeia Drug Discovery Inc | Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja |
| US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| EP2168968B1 (en) * | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| US8076338B2 (en) * | 2004-04-23 | 2011-12-13 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2009032703A1 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| TR201807039T4 (tr) | 2008-10-22 | 2018-06-21 | Array Biopharma Inc | Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri. |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP2566866A1 (en) * | 2010-05-05 | 2013-03-13 | Vertex Pharmaceuticals Incorporated | 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| US20150218652A1 (en) * | 2012-08-31 | 2015-08-06 | The Regents Of The Unversity Of Colorado, A Body Corporate | Methods for diagnosis and treatment of cancer |
| JP6457942B2 (ja) | 2012-10-05 | 2019-01-23 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｇｄｆ−８阻害剤 |
| HK1214830A1 (zh) | 2012-11-05 | 2016-08-05 | Foundation Medicine, Inc. | 新型ntrk1融合分子及其应用 |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| HK1222173A1 (zh) * | 2013-02-01 | 2017-06-23 | Bayer Pharma Aktiengesellschaft | 取代的吡唑并嘧啶基氨基-吲唑类 |
| CN103965199B (zh) | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| ES2674705T3 (es) | 2013-02-21 | 2018-07-03 | Calitor Sciences, Llc | Compuestos heteroaromáticos como moduladores de la quinasa PI3 |
| EP2970307B1 (en) | 2013-03-13 | 2020-03-11 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| BR112016008541B1 (pt) | 2013-10-17 | 2022-11-22 | Blueprint Medicines Corporation | Composto ou sal farmaceuticamente aceitável, uso do mesmo para tratar mastocistose, tumor do estroma gastrointestinal e leucemia, e composição farmacêutica |
| AU2014339972B9 (en) | 2013-10-25 | 2019-05-30 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| WO2015157093A1 (en) | 2014-04-08 | 2015-10-15 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| HRP20240937T1 (hr) | 2014-12-15 | 2024-10-25 | Cmg Pharmaceutical Co., Ltd. | Heteroaril spoj sa kondeziranim prstenom i njihova primjena kao trk inhibitora |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| WO2016133838A1 (en) | 2015-02-20 | 2016-08-25 | Rigel Pharmaceuticals, Inc. | Gdf-8 inhibitors |
| KR20180048635A (ko) | 2015-07-24 | 2018-05-10 | 블루프린트 메디신즈 코포레이션 | Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물 |
| RU2744974C2 (ru) | 2015-08-26 | 2021-03-17 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk |
| IL302209B2 (en) | 2015-11-02 | 2024-06-01 | Blueprint Medicines Corp | Inhibitors of ret |
| CA3005741A1 (en) | 2015-11-19 | 2017-05-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| EP4285996A3 (en) | 2016-04-15 | 2024-01-10 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US20190192522A1 (en) | 2016-09-08 | 2019-06-27 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors |
| CN107844168B (zh) | 2017-11-23 | 2020-12-01 | 英业达科技有限公司 | 主板组件及其卡扣装置 |
-
2016
- 2016-08-25 RU RU2018110379A patent/RU2744974C2/ru active
- 2016-08-25 EP EP16763630.7A patent/EP3341374A1/en not_active Withdrawn
- 2016-08-25 MX MX2018002407A patent/MX2018002407A/es unknown
- 2016-08-25 KR KR1020187008146A patent/KR20180043810A/ko not_active Withdrawn
- 2016-08-25 CA CA2995997A patent/CA2995997A1/en not_active Abandoned
- 2016-08-25 WO PCT/US2016/048698 patent/WO2017035354A1/en not_active Ceased
- 2016-08-25 BR BR112018003588A patent/BR112018003588A2/pt not_active IP Right Cessation
- 2016-08-25 AU AU2016311426A patent/AU2016311426B2/en not_active Expired - Fee Related
- 2016-08-25 HK HK18114466.6A patent/HK1255330A1/zh unknown
- 2016-08-25 JP JP2018510406A patent/JP6877407B2/ja not_active Expired - Fee Related
- 2016-08-25 CN CN201680060799.0A patent/CN108137607B/zh not_active Expired - Fee Related
- 2016-08-26 AR ARP160102616A patent/AR105836A1/es unknown
- 2016-08-26 TW TW105127561A patent/TW201713665A/zh unknown
- 2016-08-26 US US15/248,207 patent/US10017512B2/en active Active
-
2018
- 2018-02-22 PH PH12018500397A patent/PH12018500397A1/en unknown
- 2018-02-25 IL IL257702A patent/IL257702A/en unknown
- 2018-03-20 ZA ZA2018/01881A patent/ZA201801881B/en unknown
- 2018-07-03 US US16/027,166 patent/US11046697B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| TRAXLER P ET AL, "USE OF A PHARMACOPHORE MODEL FOR THE DESIGN OF EGF-R TYROSINE KINASE INHIBITORS: 4-(PHENYLAMINO)PYRAZOLO not 3,4-D 3/4 PYRIMIDINES", JOURNAL OF MEDICINAL CHEMISTRY, (1997), vol. 40, no. 22, pages 3601 - 3616 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018002407A (es) | 2018-11-29 |
| JP6877407B2 (ja) | 2021-05-26 |
| IL257702A (en) | 2018-04-30 |
| AU2016311426A1 (en) | 2018-04-05 |
| ZA201801881B (en) | 2019-05-29 |
| HK1255330A1 (zh) | 2019-08-16 |
| BR112018003588A2 (pt) | 2018-09-25 |
| PH12018500397A1 (en) | 2018-08-29 |
| JP2018528200A (ja) | 2018-09-27 |
| CN108137607B (zh) | 2021-04-06 |
| CA2995997A1 (en) | 2017-03-02 |
| RU2744974C2 (ru) | 2021-03-17 |
| RU2018110379A3 (enExample) | 2019-12-26 |
| US20190169194A1 (en) | 2019-06-06 |
| CN108137607A (zh) | 2018-06-08 |
| KR20180043810A (ko) | 2018-04-30 |
| US11046697B2 (en) | 2021-06-29 |
| AR105836A1 (es) | 2017-11-15 |
| US10017512B2 (en) | 2018-07-10 |
| RU2018110379A (ru) | 2019-09-27 |
| WO2017035354A1 (en) | 2017-03-02 |
| TW201713665A (zh) | 2017-04-16 |
| US20170066773A1 (en) | 2017-03-09 |
| EP3341374A1 (en) | 2018-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016311426B2 (en) | Compounds and compositions useful for treating disorders related to NTRK | |
| US11634422B2 (en) | Inhibitors of activin receptor-like kinase | |
| JP6494624B2 (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 | |
| AU2019400110B2 (en) | Radioactive fluorine-labeled Larotrectinib compound and preparation method therefor | |
| CA3175436A1 (en) | Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors | |
| US20070191293A1 (en) | Inhibitors of E1 activating enzymes | |
| CN104136399B (zh) | 泛素活化酶的吡唑并嘧啶基抑制剂 | |
| CN116969937A (zh) | Bcl-2抑制剂 | |
| KR20180094514A (ko) | 브루톤 티로신 키나제 억제제 및 이의 사용 방법 | |
| JP2023522863A (ja) | Ｅｇｆｒ阻害剤としての三環式化合物 | |
| WO2024178304A1 (en) | Kras modulators | |
| CN119013030A (zh) | Cdk4/6激酶的抑制剂 | |
| JP2021503447A (ja) | キナゾリノン類化合物及びその使用 | |
| TW202417449A (zh) | Cdk2抑制劑及使用彼等之方法 | |
| AU2019424628B2 (en) | 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof | |
| CN121219264A (zh) | 含有芳香双并环的化合物 | |
| CN105143162A (zh) | 合成方法 | |
| EA040675B1 (ru) | Ингибиторы активин-подобной рецепторной киназы | |
| HK1215809A1 (zh) | 制备三环化合物的方法以及可通过所述制备方法制备的三环化合物 | |
| HK1215809B (en) | Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |